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ABSTRACT
BCR/Abl protein drives the onset and progression of Chronic Myeloid Leukemia 
(CML). We previously showed that BCR/Abl protein is suppressed in low oxygen, 
where viable cells retain stem cell potential. This study addressed the regulation of 
BCR/Abl protein expression under oxygen or glucose shortage, characteristic of the 
in vivo environment where cells resistant to tyrosine kinase inhibitors (TKi) persist. 
We investigated, at transcriptional, translational and post-translational level, the 
mechanisms involved in BCR/Abl suppression in K562 and KCL22 CML cells. BCR/abl 
mRNA steady-state analysis and ChIP-qPCR on BCR promoter revealed that BCR/abl 
transcriptional activity is reduced in K562 cells under oxygen shortage. The SUnSET 
assay showed an overall reduction of protein synthesis under oxygen/glucose shortage 
in both cell lines. However, only low oxygen decreased polysome-associated BCR/
abl mRNA significantly in KCL22 cells, suggesting a decreased BCR/Abl translation. 
The proteasome inhibitor MG132 or the pan-caspase inhibitor z-VAD-fmk extended 
BCR/Abl expression under oxygen/glucose shortage in K562 cells. Glucose shortage 
induced autophagy-dependent BCR/Abl protein degradation in KCL22 cells. Overall, 
our results showed that energy restriction induces different cell-specific BCR/Abl 
protein suppression patterns, which represent a converging route to TKi-resistance of 
CML cells. Thus, the interference with BCR/Abl expression may sensitise environment-
adapted CML cells to current therapy.
INTRODUCTION
Chronic myeloid leukemia (CML) is a 
hematopoietic stem cell-derived and progenitor-driven 
myeloproliferative disorder that may progress from a 
clinically manageable chronic phase to an incurable 
“blastic” phase [1]. CML is characterized by the t(9;22)
(q34;q11) reciprocal translocation and the consequent 
generation of a chimeric BCR/abl oncogene, encoding for 
a 210-kDa fusion oncoprotein (BCR/Abl), endowed with 
constitutive tyrosine kinase activity, which is essential for 
CML onset, maintenance and progression [1]. The BCR/
Abl oncoprotein activates several downstream pathways, 
responsible for the inhibition of programmed cell death, 
induction of cell proliferation, block of cell differentiation, 
and loss of adhesion [2]. Consequently, BCR/Abl 
represents the primary target of CML therapy [3], which is 
based on tyrosine kinase inhibitors (TKi) targeting BCR/
Abl enzymatic activity. TKi, however, although extremely 
effective in inducing remission of the disease, are unable 
in most cases to prevent relapse [4]. 
Low oxygen (O2) tension is a critical aspect of 
the metabolic milieu where stem cells (SC) are long-
term maintained [5]. In “physiologically hypoxic” SC 
niches, low O2 tension offers a selective advantage to the 
maintenance of hematopoietic SC with respect to less 
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immature progenitors [6, 7]. We also found that low O2 
restrains the clonal expansion of SC without blocking their 
cycling, thereby contributing to maintain SC potential [8].
Cancer SC (CSC), like normal SC, most likely rely 
on metabolically-restricted environments for the regulation 
of the balance between self-renewal/maintenance and 
clonal expansion/differentiation [9, 10]. CSC homing 
within SC niches is indeed the best candidate mechanism 
to sustain the so-called minimal residual disease (MRD) 
and thereby the risk of relapse of the disease even in 
patients who brilliantly responded to antiblastic treatments 
[4]. Thus, conditions enabling CSC homing within SC 
niches are worth being characterized to try to optimize the 
long-term outcome of therapy.
As far as CML is concerned, we previously 
demonstrated that the leukemia stem cell (LSC) 
phenotype is preserved under metabolic restrictions 
(O2 and/or glucose shortage) which suppress BCR/Abl 
protein expression [11, 12]. Metabolically selected LSC 
are thereby refractory to Imatinib mesylate (IM) and 
most probably to all other BCR/Abl-targeting TKi. This 
points to the metabolic regulation of CML cell phenotype, 
namely of the presence or absence of expressed BCR/Abl 
protein, as an important factor controlling the onset of 
TKi-resistant Minimal Residual Disease (MRD) and the 
related relapse of disease [4].
The understanding of the regulation of BCR/Abl 
protein expression under metabolic pressure suffers from 
significant gaps. In this study, we addressed the effects 
of CML cell incubation under O2 or glucose shortage and 
determined how these metabolic constraints drive BCR/
Abl protein suppression. We identified multiple cell-
specific BCR/Abl suppression patterns, each cell line 
exhibiting a characteristic combination of transcriptional, 
translational and post-translational mechanisms. 
RESULTS
Effect of oxygen and/or glucose shortage on 
CML cell survival and growth 
We previously demonstrated that incubation of K562 
cells for 7 days in O2 shortage results in BCR/Abl protein 
suppression, which parallels glucose exhaustion in culture 
medium [12]. In the study reported here, we addressed 
the effects of O2 (0.1%) or glucose shortage separately, 
comparing K562 with KCL22 CML cells, aiming at the 
characterization of molecular mechanism driving BCR/
Abl protein suppression. As shown in Figure 1A, under 
standard culture conditions (21% O2 w/ glucose), K562 
cell number increased about 5-fold over the first 3 days of 
incubation, to decrease thereafter as an effect of culture 
crowding. Under glucose and, even more, O2 shortage, cell 
number increase was significantly reduced. The combined 
O2/glucose shortage was a too stringent condition, 
impairing cell number and zeroing the number of viable 
cell on day 2 of culture. Thus, we decided to exclude this 
condition from further experiments. Figure 1B shows that 
KCL22 cells behaved likewise, although with a 2–3 day 
delay of cell number peaking and decrease when compared 
to K562 cells. The Annexin V/PI assay showed a small 
amount of cell death/apoptosis during the time frame of 
our further experiments (Supplementary Figure S1).
BCR/Abl protein is suppressed in CML cells 
under oxygen or glucose shortage
We then assessed by Western blotting a 7-days 
kinetics of BCR/Abl protein levels in K562 and KCL22 
cells incubated in low O2 or in the absence of glucose. 
Either O2 (top panels) or glucose (bottom panels) shortage 
determined a time-dependent suppression of BCR/
Abl protein in K562 cells. This suppression was faster 
under O2 restriction (Figure 2A) with respect to that 
under glucose restriction. KCL22 cells behaved likewise 
(Figure 2B), although suppression occurred more slowly 
than in K562 cells. These cell line-specific differences of 
BCR/Abl protein suppression kinetics, when evaluated 
together with those relative to the reduction of CML cell 
number (Figure 1), seem to indicate that this reduction 
followed BCR/Abl suppression, in keeping with previous 
conclusions [12]. 
BCR/abl mRNA is differentially expressed under 
oxygen or glucose shortage
The mechanisms driving BCR/Abl protein 
suppression were deepened analyzing multiple levels of 
BCR/abl gene expression under metabolic restriction. We 
evaluated first the total BCR/abl mRNA relative amount. 
Figure 3A (left panel) shows a significant reduction 
of BCR/abl mRNA in K562 cells as early as day 1 of 
incubation in low O2, to decrease further in the following 
days. On the contrary, glucose shortage did not alter BCR/
abl mRNA level in K562 cells (Figure 3A, right panel). 
As far as KCL22 cells are concerned (Figure 3B), neither 
O2 (left panel) nor glucose (right panel) shortage led to 
the reduction of BCR/abl mRNA level over 7 days of 
incubation. Overall, these results suggested the existence 
of cell line- and metabolic condition-specific mechanisms 
of BCR/Abl protein suppression under energy restriction.
Transcriptional regulation of BCR/abl mRNA in 
K562 cells under oxygen shortage
On the basis of the results of Figure 3A, we 
determined whether the decrease of BCR/abl mRNA in 
K562 cells incubated in low O2 could be attributed to an 
altered mRNA stability or to a reduced transcriptional 
activity. Cells were treated with the transcriptional 
inhibitor actinomycin D and BCR/abl mRNA levels 
were monitored by qPCR every 2 hours for 8 hours after 
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treatment (Figure 4A). BCR/abl mRNA half-life, as 
determined by polynomial best fit of data obtained, was 
2.5 hours for incubation in low O2 versus 2.4 hours in 
standard conditions, indicating that O2 shortage does not 
significantly affect BCR/abl mRNA half-life. Therefore, 
we investigated if transcriptional activity was reduced in 
K562 under O2 shortage evaluating BCR promoter activity 
(Figure 4B). BCR promoter controls the transcription 
of both BCR and BCR/abl genes [13]. K562 cells were 
incubated for 36 hours in low O2 or under standard 
conditions and then ChIP-qPCR was performed to detect 
acetylated histone H4 at the BCR promoter. H4 acetylation 
is generally associated with chromatin unfolding and 
transcription initiation [14, 15]. O2 shortage significantly 
reduced the level of H4 acetylated at the BCR promoter 
in keeping with a reduced expression of BCR/abl mRNA. 
Translational control of BCR/Abl protein under 
oxygen or glucose shortage
To evaluate if translational machinery also regulates 
BCR/Abl protein expression under energy restriction, we 
performed the SUnSET (surface sensing of translation) 
assay and polysome profiling analysis. 
The SUnSET assay allows to determine the mRNA 
translational rate based on incorporation of puromycin into 
nascent polypeptide chain [16]. To determine the optimal 
concentration of puromycin for our experiments, we assayed 
puromycin incorporation and we found that 1 μg/mL 
produced the best signal, with a greater proportion of labeled 
high molecular weight proteins, indicating minimal protein 
truncation and degradation (Supplementary Figure S2) 
[17]. Figure 5A and 5B show that puromycin incorporation 
decreased progressively upon either O2 (top panels) or 
glucose shortage (bottom panels) in both K562 and KCL22 
cells, indicating that protein synthesis is restrained during 
energy restriction. To evaluate the specificity of the assay, 
we also pretreated cells with the translation inhibitor 
cycloheximide that, as expected, completely blocked 
puromycin incorporation.
Further, BCR/abl mRNA translation was deepened 
by investigating its polysomal loading. A change in the 
association of mRNA with polysomes is indicative of 
changes in its translation state [18]. We performed sucrose 
gradient fractionation of cytoplasmic sub-polysomal 
(representative of non-translating monosomes) and 
polysomal RNA (representative of actively translating 
poly-ribosomes) from K562 or KCL22 cells incubated 
under O2 or glucose shortage (Figure 5C and 5D). The 
polysome profile in lysates of untreated cells (time 0) 
showed three defined peaks (40S, 60S, and 80S) in the 
less dense fractions (1 to 6) and increasing levels of 
polysomal RNA (i.e. numbers of associated ribosomes) 
in the denser fractions (7 to 12). Low O2 conditions 
resulted in a shift to free ribosomal subunits and a marked 
decrease of polysomal RNA in both K562 and KCL22 
cells; polysomal profiles from glucose shortage conditions 
showed no qualitative differences with respect to time 0. 
RNA fraction analyses in KCL22 cells showed that low 
O2 reduced the polysomal loading of BCR/abl mRNA 
with respect to time 0, while increasing the sub-polysomal 
fractions (Figure 5E). These data were also supported by 
the quantification of the BCR/abl mRNA level in collected 
sub-polysomal (fraction 1 to 6) and polysomal (fraction 
Figure 1: Effects of oxygen and/or glucose shortage on CML cell survival and growth. K562 (A) or KCL22 (B) cells were 
plated at 3 × 105 cells/mL and incubated at 21% O2 w/ glucose (♦) or 21% O2 w/o glucose (■), and at 0.1% O2 w/ glucose (▲) or 0.1% O2 
w/o glucose (X). Viable cells were counted by trypan blue exclusion at the indicated times. The graphs show means ± SD of 7 independent 
experiments. K562 cells: p ≤ 0.01 (♦) compared with (■), (▲) from day 2, (X) from day 1; p ≤ 0.01 (■) compared with (▲) from day 3 to 
day 8. KCL22 cells: p ≤ 0.01 (♦) compared with (■), (▲) from day 2, (X) from day 1; p ≤ 0.01 (■) compared with (▲) from day 2 to day 
9 (two-tailed Student’s t test).
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Figure 2: BCR/Abl protein suppression under oxygen or glucose shortage. K562 (A) or KCL22 (B) cells were incubated at 
0.1% O2 in standard medium (top panels) or 21% O2 in the absence of glucose (bottom panels) for the indicated times. The levels of BCR/
Abl protein were determined by Western blotting using α-Tubulin as loading control. Band intensity was quantified using the Odyssey 
software. Data were normalized with respect to the corresponding α-Tubulin band intensity and expressed as percentage of time 0 (day 0) 
value. UN: undetectable. Histograms represent the mean + SD of 3 independent experiments; **p ≤ 0.01, *p ≤ 0.05 compared with time 0; 
°p ≤ 0.05 compared with day 1 (two-tailed Student’s t test).
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7 to 12) compartments (Figure 5F). The results indicated 
that the poly/sub-poly ratios decreased significantly (p ≤ 
0.05) under O2 shortage in KCL22 cells. Glucose shortage, 
on the contrary, did not reduce these ratios significantly in 
KCL22 cells (data not shown). Finally, in K562 cells, the 
association of BCR/abl mRNA with the actively translated 
fractions did not change in either O2 or glucose shortage 
(data not shown).
Overall, these data highlighted the strong 
contribution of translational regulation resulting in 
reduced production of BCR/Abl protein under low oxygen 
conditions in KCL22 cells. By contrast, in K562 cells, 
alterations of BCR/Abl translation did not seem to be 
involved, despite the evident reduction of protein synthesis 
under either O2 or glucose shortage.
Post-translational control of BCR/Abl protein 
suppression under oxygen or glucose shortage
To explore the contribution of post-translational 
control mechanisms of BCR/Abl protein, we also 
determined the involvement of the proteasome machinery. 
K562 and KCL22 cells were incubated under oxygen 
or glucose shortage in the presence or the absence of the 
proteasome inhibitor MG132. As shown in Supplementary 
Figure S3, we preliminarily determined the optimal 
concentration of MG132 for each cell line: 0.3 µM for 
K562 cells and 0.1 µM for KCL22 cells. These MG132 
concentrations inhibited the ubiquitin-proteasome machinery 
(Supplementary Figure S3A and S3D) and did not affect cell 
survival (Supplementary Figure S3B and S3E) or induce 
apoptosis (Supplementary Figure S3C and S3F). Under 
either O2 (Figure 6A, top panel) or glucose shortage (Figure 
6A, bottom panel), the maintenance of BCR/Abl protein in 
K562 cells was significantly enhanced in cultures treated 
with MG132. Thus, the proteasome activity was strongly 
involved in BCR/Abl protein suppression under energy 
restrictions in K562 cells. On the other hand, in KCL22 
cells, MG132 treatment had no effects (data not shown). 
To determine whether BCR/Abl protein suppression 
was also due to the activation of caspases, we assessed 
the effect of the pan-caspase inhibitor z-VAD-fmk. 
Figure 3: BCR/abl mRNA expression under oxygen or glucose shortage. K562 (A) or KCL22 (B) cells were incubated at 0.1% 
O2 in standard medium (left panels) or at 21% O2 in the absence of glucose (right panels) for the indicated times. BCR/abl mRNA was 
measured by qPCR and its quantity expressed as percentage of time 0 value. Data were normalized within each experiment using different 
housekeeping genes and the results from different experiments mediated. The genes, chosen because their expression did not change under 
the experimental condition used, were: for O2 shortage, GAPDH, 18S, β-actin and GUSB for K562 cells and GAPDH, 18S, EIF2a and 
β-2 microglobulin for KCL22 cells; for glucose shortage, GAPDH and β-actin for either cell line. Data are mean + SD of 3 independent 
experiments; **p ≤ 0.01 compared with day 0; °p ≤ 0.05 day 2 and day 3 compared with day 1; °p ≤ 0.05 day 3 compared with day 2 (two-
tailed Student’s t test).
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Inhibition of PARP cleavage showed that 50 µM z-VAD-
fmk protected K562 and KCL22 from apoptosis under 
either experimental condition (Supplementary Figure S4). 
Figure 6B shows that, under O2 (top panel) or glucose 
shortage (bottom panel), the maintenance of BCR/
Abl protein in K562 cells was significantly enhanced 
in cultures treated with z-VAD-fmk. Thus, caspases 
contribute to BCR/Abl protein suppression under energy 
restriction in K562 cells. Differently, in KCL22 cells, 
z-VAD-fmk treatment had no effects (data not shown). 
The combined treatment with MG132 and z-VAD-
fmk in K562 cells showed no synergistic or additive 
effects (Supplementary Figure S5).
In order to assess whether autophagy was involved 
in BCR/Abl protein suppression under energy restrictions, 
we first analyzed the microtubule-associated protein light 
chain 3 (LC3), the main marker of autophagosomes, 
in K562 and KCL22 cells subjected to O2 or glucose 
shortage. Autophagy is characterized by the accumulation 
of the cleaved and lipidated form of LC3 (LC3-II) [19]. 
Glucose shortage induced marked accumulation of LC3-
II in KCL22 cells, starting from day 2 (Figure 7A), while 
only a slight LC3-II increase occurred in K562 cells 
(Supplementary Figure S6A, right panel). On the contrary, 
O2 shortage showed no LC3 activation in either cell line 
(Supplementary Figure S6A left panel: K562 cells, and 
S6B: KCL22 cells), indicating that autophagy was not 
involved in BCR/Abl protein suppression in low O2. To 
confirm that LC3-II increase in KCL22 cells under glucose 
shortage was actually due to an active autophagic flux, we 
evaluated the LC3-II level in the presence or absence of 
bafilomycin A1. This is a specific inhibitor of vacuolar-
type H+-ATPase, which inhibits autophagy at a late 
stage by increasing the lysosomal intracellular pH, thus 
preventing the fusion of autophagosomes and lysosomes 
and the consequent degradation of autophagic proteins 
[20, 21]. Thus, a further LC3-II increase in the presence of 
bafilomycin A1 reflects an actual induction of autophagy 
[19]. Confocal microscopy with LC3 immunofluorescence 
revealed an increased punctate staining in KCL22 cells 
maintained under glucose shortage for 4–5 days with 
respect to time 0 (Figure 7B, upper panels). In bafilomycin 
A1-treated cells this effect was enhanced, as expected; 
the treatment with high-dose chloroquine was used as 
a positive control for the inhibition of autophagic flux 
(Figure 7B, lower panels). LC3-II protein increase after 
bafilomycin A1 treatment was further confirmed by 
Western blotting (Figure 7C, upper blot). To directly link 
autophagy to BCR/abl protein suppression under glucose 
shortage, we determined the BCR/Abl protein level in 
the presence or absence of bafilomycin A1. As shown in 
Figure 7C (lower blot and histograms), BCR/Abl protein 
level was significantly increased in bafilomycin A1-treated 
KCL22 cells with respect to untreated control. In K562 
cells, on the contrary, bafilomycin A1 treatment did not 
determine BCR/Abl protein maintenance (data not shown). 
These results demonstrated the autophagic degradation of 
BCR/Abl protein under glucose shortage in KCL22 cells.
Figure 4: Effects of oxygen shortage on BCR/abl mRNA stability and BCR promoter activity. (A) K562 cells were incubated 
at 0.1% or 21% O2 in standard medium for 8 hours in the presence of the transcriptional inhibitor actinomycin D (5 μg/mL). Cells were 
harvested every 2 hours and qPCR for BCR/abl was performed. GAPDH was used as housekeeping gene. BCR/abl quantity was normalized 
by the ratio of BCR/abl to GAPDH mRNA and expressed as percentage of time 0 (h 0) value. Data are mean ± SD of 3 independent 
experiments. Interpolating curves were determined by polynomial best fit (R2 = 0.982 for 0.1% O2 and 0.994 for 21% O2). (B) K562 cells 
were incubated at 0.1% or 21% O2 in standard medium for 36h and lysed. ChIP was performed using an antibody against acetylated histone 
H4 (acH4) and a control rabbit IgG (rIgG) followed by qPCR for the BCR promoter. Histograms represent the relative quantification of 
DNA recovered from IP. Data were normalized for input values and expressed as fold-enrichment with respect to control IgG; the fold-
enrichment value obtained for 21% O2 was arbitrarily set to 100%. Data are mean + SD of 3 independent experiments; *p ≤ 0.05 (two-tailed 
Student’s t test).
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DISCUSSION
This work provides a mechanistic explanation to 
the previous findings of ours that BCR/Abl protein is 
suppressed under energy restriction [11, 12]. We found 
here that, in K562 cells, O2 shortage reduced BCR/
abl mRNA levels as well as BCR/abl promoter activity, 
while either O2 or glucose shortage led to proteasome- 
and caspase-dependent BCR/Abl protein degradation. 
On the other hand, in KCL22 cells, O2 shortage reduced 
BCR/Abl translation, while glucose shortage induced 
autophagy-dependent BCR/Abl protein degradation 
Figure 5: Effects of oxygen or glucose shortage on BCR/Abl translation. K562 (A) or KCL22 (B) cells were incubated at 0.1% 
O2 in standard medium (top panels) or at 21% O2 in the absence of glucose (bottom panels) for the indicated times and treated with 1 µg/
mL of puromycin (Puro) for 6 hours. Cell extracts were separated by denaturing electrophoresis and analyzed by Western blotting with a 
monoclonal antibody to puromycin (12D10), using α-Tubulin as loading control. As relative to puromycin signal, the intensity of entire 
lanes was quantified using the Odyssey software. Data were normalized with respect to the corresponding α-Tubulin band intensity and 
expressed as percentage of time 0 value for puromycin-treated cells. Histograms represent the mean + SD of 3 independent experiments; 
*p ≤ 0.05 compared with time 0 puromycin-treated (two-tailed Student’s t test). K562 (C) or KCL22 (D) cells were incubated at 0.1% O2 
in standard medium or at 21% O2 in the absence of glucose. Prior to cell lysis, ribosomes were immobilized on the mRNA by the treatment 
with the translation elongation inhibitor cycloheximide at 100 μg/mL final concentration for 15 min. Cytosolic extracts were fractionated 
over a 15 to 50% sucrose gradient, and the absorbance at 254 nm (A254) of sub-polysomal (1 to 6) and polysomal (7 to 12) fractions was 
continuously monitored. The positions of the 40S, 60S, 80S and polysomal peaks for time 0 are indicated. Results are representative of 
3 independent experiments. qPCR analysis of relative BCR/abl mRNA levels in single cytoplasmic RNA fractions (E) and pooled sub-
polysomal (FRAC 1-6) and polysomal (FRAC 7-12) fractions (F) of KCL22 cells subjected to 0.1% O2 in standard medium; data are mean 
+ SD of 3 independent experiments; *p ≤ 0.05 compared with time 0 (two-tailed Student’s t test).
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Figure 6: Effect of proteasome or caspase inhibition on BCR/Abl protein suppression under oxygen or glucose 
shortage. K562 cells were incubated at 0.1% O2 in standard medium (top panels) or 21% O2 in the absence of glucose (bottom panels) for 
the indicated times, treated with the proteasome inhibitor MG132 (0.3 µM) (A) or the pan-caspase inhibitor z-VAD-fmk (50 µM) (B) for 
the indicated times and lysed. BCR/Abl protein expression was determined by Western blotting using α-Tubulin as loading control. Band 
intensity was quantified using the Odyssey software. Data were normalized with respect to the corresponding α-Tubulin band intensity and 
expressed as percentage of time 0 (day 0) value. Histograms represent the mean + SD of 3 independent experiments; **p ≤ 0.01, *p ≤ 0.05 
compared with untreated (two-tailed Student’s t test).
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Figure 7: Role of autophagy in BCR/Abl protein suppression under glucose shortage. KCL22 cells were incubated at 
21% O2 in the absence of glucose for the indicated times. (A) LC3-I and LC3-II levels were determined by Western blotting, using 
α-Tubulin as loading control. (B) Following treatment with the late-stage autophagy inhibitor Bafilomycin A1 (2 nM) added on day 3, 
cells were incubated for further 1 or 2 days and the expression of LC3 was then assessed by immunofluorescence. Treatment with 100 µM 
Chloroquine for 24 h was used as a positive control of autophagic flux inhibition. Nuclei were stained by Hoechst 33342. (C) Following 
treatment with Bafilomycin A1 on day 3, cells were incubated for further 1 or 2 days and lysed. LC3-I and LC3-II (top blot), and BCR/Abl 
(lower blot) protein levels were determined by Western blotting using α-Tubulin as loading control. BCR/Abl band intensity was quantified 
using the Odyssey software. Data were normalized with respect to the corresponding α-Tubulin band intensity and expressed as percentage 
of time 0 (day 0) value. Histograms represent the mean + SD of 3 independent experiments; **p ≤ 0.01 compared with untreated (two-tailed 
Student’s t test).
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(Figure 8). Thus, a complex scenario emerged where the 
two cell lines behaved quite differently, yet converging 
to BCR/Abl protein suppression. These differences likely 
derive from the fact that K562 and KCL22 cells, although 
originating both from CML blast-crisis patients, exhibit 
a different phenotype, as witnessed by the quite different 
proteome profiles [22]. Our evidences led to conclude that 
energy restriction induces cell line-specific, multi-layer 
BCR/Abl suppression patterns, each cell line exhibiting a 
characteristic combination of transcriptional, translational 
and post-translational mechanisms of suppression. This 
underscores the necessity of CML cells subjected to 
energy restriction to undertake a process leading to BCR/
Abl protein suppression regardless of the molecular 
mechanisms involved.
A top-down conceptual process commanded to 
explore first the role of BCR/abl transcription. O2 shortage 
caused a significant reduction of BCR/abl mRNA levels as 
well as BCR/abl promoter activity in K562 cells. Reduced 
BCR promoter activity has been found upon myeloid 
differentiation from hematopoietic SC to common myeloid 
progenitors [23, 24]. This activity is maintained in chronic-
phase CML and overactivated in blast crisis, leading to 
BCR and BCR/Abl overexpression [13]. Furthermore, 
BCR/abl transcription is controlled by the Sp1 (Specificity 
protein 1) and Myc transcription factors and via histone H4 
hyperacetylation [25–28]. Noteworthy, Myc and Sp1 are 
involved in the transcriptional program leading to hypoxic 
adaptation [29, 30]. Our evidences indicated that, while 
glucose, differently from O2, shortage did not determine 
the reduction of BCR promoter activity in K562 cells, both 
conditions reduced cell number in culture. This suggests that 
reduction of BCR promoter activity is not directly linked to 
block of proliferation, but is rather a specific consequence 
of hypoxic signaling, possibly related to some of the above-
mentioned transcriptional or epigenetic regulators.
Figure 8: Summary of the multi-layer BCR/Abl protein suppression pattern under energy 
restriction.
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KCL22 cells under O2 shortage underwent reduction 
of BCR/Abl protein translation. Translation is a very 
energy-demanding process [31], which is in general shut 
down under oxygen or glucose shortage [32]. Anyhow, 
non-canonical or cap-independent mechanisms of 
translation initiation ensure synthesis of proteins whose 
expression has to be preserved under stress conditions 
[33]. Consistent with these evidences, we found that both 
K562 and KCL22 cells underwent overall translational 
inhibition under O2 and glucose shortage. Surprisingly, 
BCR/Abl translation rate was reduced only in KCL22 
cells, and only under O2 shortage. On this basis, we 
hypothesize that BCR/Abl translation could bypass 
canonical cap-dependent mRNA recruitment. However, 
this hypothesis requires further investigations. 
At the post-translational level, we explored the 
involvement of proteasome, caspases and autophagy in 
BCR/Abl degradation. We demonstrated that in K562 
cells, under either O2 or glucose shortage, BCR/Abl 
protein suppression relies on proteasomal degradation. 
Proteasomal degradation of immature BCR/Abl protein 
has been observed in the absence of its Hsp90-mediated 
proper folding, following protein recognition by the E3-
ubiquitin ligase CHIP (Carboxyl terminus of Heat shock 
cognate protein 70 (Hsc70)-Interacting Protein) and the 
involvement of Bag1 (Bcl-2-associated athanogene-1) 
protein. In addition, the E3-ubiquitin ligase c-Cbl (Casitas 
b-lineage lymphoma) induces degradation of mature 
and phosphorylated BCR/Abl protein [34]. Moreover, 
it has been demonstrated that β-TrCP (β-Transducing 
repeat Containing Protein) upregulation results in 
enhanced BCR/Abl ubiquitination and its consequent 
degradation in K562 cells [35]. As for caspases, we 
showed their role in BCR/Abl protein suppression in 
K562 cells under either O2 or glucose shortage, in keeping 
with what previously described for K562 undergoing 
erythroid differentiation [36]. The ubiquitin-proteasome 
system (UPS) has an important role in apoptosis [37]. 
However, depending on the cell type, interference with 
UPS protects from or triggers apoptosis, via caspase 
degradation or mitochondrial cytochrome C release and 
caspase activation, respectively [38, 39]. Thus, a fine 
balance between UPS and caspases exists to regulate cell 
fate decisions [39]. Finally, we found that autophagy led 
to BCR/Abl protein degradation in KCL22 cells under 
glucose shortage. Autophagy is part of the cell’s survival 
response to stress, including energy shortage [40]. Taken 
together, our results indicated that post-translational 
mechanisms are heavily involved in the inhibition of the 
BCR/Abl-dependent proliferation signals in CML cells.
The link between energy shortage and environmental 
conditions where stem cells responsible for late relapse 
of disease are maintained underscores the interest for 
the characterization of the mechanisms of BCR/Abl 
suppression. We strongly believe that, under energy 
restriction, the balance within the CML cell population 
between clonal expansion and stem cell persistence is 
shifted towards the latter. As a consequence, proliferative 
stimuli such as those derived from BCR/Abl need to be 
suppressed within the stem cell environment [41]. The 
so-called “stem cell niche”, hematopoietic in particular, 
is a physiologically “hypoxic/ischemic” environment. 
In this context, the complex pattern of BCR/Abl protein 
suppression emerging from our results appears as an 
essential convergent aspect of CML cell adaptation to niche 
environment [42]. Cancer is indeed an evolutionary process 
at the cellular level, driven by stochastic genomic alterations 
which are selected by the interaction with microenvironment 
[43–45]. In this respect, it has been proposed that 
cancerogenesis is driven by a reverse evolution from 
multicellularity to unicellularity, where individual cancer 
cells increase their fitness to environment via the loss of 
multicellularity-related genetic constraints [46]. This is why 
evolution pushes cancer cells of different types and origins 
towards a convergent fate via different routes [42–47]. In 
conclusion, the concept emerging from our findings is that, 
in the course of CML cell adaptation to environmental 
metabolic constraints, BCR/Abl protein suppression is a 
mandatory phenomenon, driven via different routes as a 
common final target of the adaptation process.
BCR/Abl represents the “sole” oncogenic driver 
of CML [48] and one for which an extremely effective 
“biological” therapy -TKi- has been developed. However, 
minor CML cell subsets find their way to escape from 
TKi sensitivity, for a variety of reasons, including BCR/
Abl protein suppression [49]. TKi are able in fact to 
target the CML bulk, but not to eliminate CML stem cells 
[50–53], well in keeping with BCR/Abl suppression in 
niche-adapted stem cells [4]. Thus, the cell line-specific 
BCR/Abl suppression mechanisms represent different 
routes converging to CML cell resistance to therapy. The 
post-translational mechanisms taken into consideration 
in our study have been shown involved in the resistance 
of CML stem cells to TKi [54–57]. Furthermore, our 
findings hint to the possibility of using inhibitors of 
autophagy, apoptosis or proteasome to maintain BCR/
Abl protein expression in LSC and thereby to target their 
adaptation to the stem cell niche. In this respect, it has 
been demonstrated, for instance, that autophagy acts as a 
survival signal in BCR/Abl-expressing cells treated with 
TKi and that its inhibition potentiates TKi-induced cell 
death, besides targeting the TKi-resistant CML stem cell 
population [58]. This may results in an improvement of 
current CML therapy aiming at the eradication of disease.
MATERIALS AND METHODS
Cells and culture conditions
Human K562 and KCL22 blast-crisis CML cell 
lines were purchased from German Collection of Cell 
Cultures (Braunschweig, Germany) and grown as 
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previously described [12]. Full details are provided in the 
Supplementary Materials and Methods.
Cell death/apoptosis
Determination of CML cell death/apoptosis was 
carried out by Annexin-V-FLUOS Staining kit (cat. 
1858777, from Roche Diagnostics GmbH, Penzberg, 
Germany) according to the manufacturer’s instructions. 
Briefly, cells (at a concentration of 1 × 106 cells/mL) were 
washed with PBS and resuspended in 100 μL of Incubation 
buffer cointaining Annexin-V-Fluos labeling reagent and 
Propidium iodide (PI) solution and were incubated in the 
dark for 15 min at room temperature. Further 400 μL of 
Incubation buffer were added and the cells were analyzed 
immediately using a FACSCanto (Becton-Dickinson, 
Franklin Lakes, NJ, U.S.A.) flow cytometer. Data from 
at least 20000 events per sample were recorded and 
processed using BD FACSDiva™ software (Becton-
Dickinson), and the % of Annexin V +/– and PI +/– cells 
were quantified using FlowJo software (FlowJo LLC, 
Ashland, OR, U.S.A.).
Protein extraction and Western blotting
Proteins were extracted and separated essentially 
as previously described [12]. Full details of the protein 
extraction and Western blotting are provided in the 
Supplementary Materials and Methods. Primary antibodies 
used were: anti-phospho-c-Abl (Tyr245), rabbit polyclonal 
(cat. 2861), and anti-cleaved-PARP (Asp214), rabbit 
polyclonal (cat. 9541), anti LC3 A/B, rabbit polyclonal 
(cat. 4108) (all from Cell Signaling Technology Danvers, 
MA, U.S.A.); anti-α-Tubulin (clone DM1A), mouse 
monoclonal (cat. T9026, from Sigma-Aldrich, St. Louis, 
MO, U.S.A.); anti-c-Abl (K-12), rabbit polyclonal (cat. 
sc-131), anti-ubiquitin (P4D1), mouse monoclonal (cat. 
sc-8017) (all from Santa Cruz Biotechnology, Santa 
Cruz, CA, U.S.A.); anti-puromycin mouse monoclonal 
(cat. MABE343, Merck Millipore). After washing with 
T-PBS, membranes were incubated for 1 h at RT in 1:1 
OBB/PBS containing an IRDye®800CW- or IRDye®680-
conjugated secondary antibody. Antibody-coated protein 
bands were visualized by the Odyssey Infrared Imaging 
System Densitometry (LI-COR® Biosciences, Lincoln, 
NE, U.S.A.) and images analyzed by the Odyssey software 
to measure the mean fluorescence intensity value of the 
area selected for each band. A background measurement 
was also taken.
Real Time quantitative PCR 
Total RNA was extracted using TRIzol reagent 
(Thermo Fisher Scientific) according to the manufacturerʼs 
instructions. The concentration and purity of RNA were 
determined by absorbance at 260/280 nm, and 0.5 µg of 
RNA were used to generate cDNA using the ImProm-
IITM Reverse Transcription System (Promega, Madison, 
WI, U.S.A.) according to the manufacturerʼs protocol. 
Real Time quantitative PCR (qPCR) analysis of BCR/abl 
p210 transcript (b2a2 for KCL22 cells, b3a2 for K562 
cells) was performed with the Applied Biosystems 7500 
Fast Real-Time PCR System (Thermo Fisher Scientific): 
2 min 95°C, 40 cycles at 95°C for 15 sec, 56°C for 20 sec, 
60°C for 40 sec, and dissociation at 60–95°C for 1 cycle, 
using the GoTaq qPCR MasterMix (Promega). A melting 
curve analysis was performed to discriminate between 
specific and non-specific PCR products. Relative BCR/abl 
mRNA levels were normalized to different housekeeping 
genes, β-actin, GAPDH, 18S rRNA, GUSB, EIF2a or β-2 
microglobulin, depending on the cell line and the metabolic 
condition. The sequences of oligonucleotide primers 
(all from Integrated DNA Technologies, Coralville, IA, 
U.S.A.) are shown in Supplementary Table S1.
Analysis of mRNA stability 
The half-life of BCR-abl mRNA was determined by 
treating K562 cells with 5µg/mL Actinomycin D (Sigma-
Aldrich) to block transcription. During the following 8 h, 
cells were harvested every 2 hours and total RNA was 
extracted using TRIzol. The amounts of BCR/abl mRNA 
and GAPDH mRNA at each time point were determined 
by qPCR.
Chromatin Immunoprecipitation (ChIP) assay 
ChIP assay was performed essentially as previously 
described [59]. Full details of the ChIP assay are provided 
in the Supplementary Materials and Methods. ChIP-grade 
antibodies used (2µg) were: rabbit polyclonal anti-pan-
acetylated-H4 (cat. 06–598, Merck-Millipore), rabbit 
IgG (cat. G5518, Sigma-Aldrich). The relative amount of 
immunoprecipitated BCR promoter DNA was determined 
by qPCR using the following primers:
BCR prom FWD 5′-CTGCGAGTTCTGCCAGA 
GAG-3′,
BCR prom REV 5′-CACCCTCCCCCCGTCCC 
TGT-3′
described by [28]. The results were normalised by 
the fold-enrichment method and compared with the IgG-
negative controls.
SUnSET assay
The SUnSET assay is based on the use of 
puromycin, an aminonucleoside antibiotic produced 
by S. alboniger. Puromycin is incorporated into the 
nascent polypeptide chain and, when used in minimal 
amounts, its incorporation rate is proportional to mRNA 
translation in vitro. A monoclonal antibody to puromycin 
enables to directly monitor translation using a standard 
immunochemical method [16]. CML cells were incubated 
at 0.1% O2 in standard medium or at 21% O2 in the 
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presence or the absence of glucose with the indicated 
concentrations of puromycin (cat. P8833, Sigma Aldrich) 
for 6 hours at different times of incubation. Cells were 
then collected and subjected to Western blotting as 
described above to assess rate of protein synthesis.
Polysome profile analysis
Polysomes can be separated from free 80S 
ribosomes and ribosomal subunits by sucrose density 
gradient centrifugation, a method commonly used in 
translational control research [18]. A change in the 
association of mRNA with polysomes is indicative of 
changes in its translation state. Experimental procedures 
were performed as previously described [60]. Full details 
of the polysome profile analysis are provided in the 
Supplementary Materials and Methods.
Aliquots of cytoplasmic lysates were considered for 
sample comparison; “spike-in” in vitro transcribed Renilla 
luciferase transcript (1ng) was further added to each 
fraction, as suggested by [61], to normalize the relative 
yield after TRIzol RNA isolation. RNA samples were then 
analyzed by qPCR using BCR/abl and Renilla luciferase 
primers in an Applied Biosystems 7500 Fast Real-Time 
PCR System (Thermo Fisher Scientific): 15 min 37°C, 
10 min 95°C, 42 cycles at 95°C for 10 sec, 56°C for 
30 sec, 72°C for 30 sec, and dissociation at 60–95°C 
for 1 cycle, using the GoTaq 1-Step RT-qPCR System 
(Promega). The sequences of the used oligonucleotides 
are shown in Supplementary Table S1. 
Treatment with proteasome and/or caspase 
inhibitors
Cells were treated with the proteasome inhibitor 
MG132 (0.3 or 0.1 µM; cat. C2211, Sigma Aldrich) 
or the pan-caspase inhibitor z-VAD-fmk (50 µM; cat. 
187389-52-2, MedChem Express, Stockholm, Sweden) 
and maintained under oxygen or glucose shortage for 3 
or 4 days, respectively. On day 2 of incubation, a half-
dose of drug was added to culture. The combination of 
MG132 with Z-VAD-fmk was also tested (day 3). To 
assess the BCR/Abl protein level, Western blotting was 
then performed as described above.
Treatment with autophagy inhibitors
Cells maintained under oxygen or glucose 
shortage were treated with the late-stage autophagy 
inhibitor Bafilomycin A1 (2 nM; cat. B1793, Sigma 
Aldrich) at different times of incubation. As positive 
control of autophagic flux inhibition, a very high dose of 
Chloroquine was used (100 µM for 24 hours; cat. C6628, 
Sigma Aldrich). To assess the LC3 I/II and BCR/Abl 
protein level, Western blotting was performed as described 
above.
Immunofluorescence and confocal microscopy
Cells (1 × 105) were spun on microscope slides 
(Menzel-Gläser, by Thermo Fisher Scientific) at 800 rpm for 
6 min in a cytocentrifuge (Aerospray Pro slide stainer and 
cytocentrifuge 7152, Delcon, Milan, Italy). Slides were fixed 
for 15 min with ice-cold 100% methanol, rinsed 3 times 
with PBS, blocked with 5% horse serum and 0.3% Triton® 
X-100 (VWR) in PBS, and incubated with LC3 A/B 
antibody overnight at 4°C. Slides were then washed 3 times 
with PBS and incubated with a Cy2-conjugated secondary 
anti-rabbit antibody (cat. AP132J, Merck-Millipore) for 
1 h at room temperature. Nuclei were counterstained by 
the Hoechst 33342 stain (cat. B2261, Sigma Aldrich). 
Cells were then dried and examined with a Nikon Eclipse 
TE2000-U confocal microscope (Nikon, Tokyo, Japan). A 
single image was obtained by superimposition of 10 optical 
sections at 63x magnification for each sample using the 
ImageJ software (developed by Wayne Rasband, National 
Institutes of Health, Bethesda, MD, U.S.A. and available at 
http://rsbweb.nih.gov/ij/index.html). 
Statistical analysis
All data are presented as the mean + SD (unless 
indicated otherwise) of independent experiments and were 
compared by using a Student’s t test. P values (p) of ≤ 0.05 
were considered statistically significant.
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